PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
2023 RBC Capital Markets Global Healthcare Conference
2023 Jefferies Global Healthcare Conference
About embecta
embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors | |
| Christian Glazar | Pravesh Khandelwal | |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations | |
| 908-821-6922 | 551-264-6547 | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$19.13 |
| Daily Change: | 0.39 2.08 |
| Daily Volume: | 187,038 |
| Market Cap: | US$1.110B |
September 03, 2024 August 09, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
